The applicant is responsible for the accuracy and truthfulness of the documents and data supplied to the Agency when the application for marketing authorisation is submitted and during its examination.
The applicant must inform the Agency without delay of any new information available or of which he is aware, in particular the results of biomedical studies or research carried out in or outside the European Community or the European Economic Area, which could lead to a change in the assessment of the risk-benefit balance of the medicinal product as defined in the first paragraph of Article L. 5121-9.